The CDSCO and The Subject Expert committee has informed that COVID -19 booster dose cannot be recommended or used without clinical trials. The Serum Institute had given an application for Booster Dose of Covid-19 on December 9th, 2021 to the SII Committee. The SEC Committee has reviewed the application from the SII and has sought additional data and documents before another meeting. Amid the emergency of new Covid-19 variant Omicron, the SII has sought the approval to administer for Covishield Vaccine on the basis of lack of stock and raising of demand. The Medicines and Healthcare product regulatory agency in the UK has already approved the Booster of Astrazeneca Chadoxl NCov- 19 Vaccine. People who are fully vaccinated with two doses of Covishield have requested the firm for booster doses as mentioned in the application submitted in DCGI. Booster dose was recommended by many experts in India especially after the emergence of the Omicron. A clarification statement released by the Indian SARS-CoV-2 Genomics Consortium has also said that they never recommended a booster dose.

Morulaa is a company is specialized in Regulatory Compliance for India and Southeast Asia.  Morulaa Provides high quality and professional services for regulatory services and we aim at developing long term relationships with Manufacturers for the Indian Market. If you have any enquiry regarding the Registration of Medical Devices in India, Contact Morulaa